Literature DB >> 7972907

Impact of overall treatment time of fractionated irradiation on local control of human FaDu squamous cell carcinoma in nude mice.

M Baumann1, C Liertz, H Baisch, T Wiegel, J Lorenzen, H Arps.   

Abstract

A series of experiments were performed to determine the impact of overall treatment time on local control of human FaDu squamous cell carcinoma irradiated with 30 fractions under ambient conditions in nude mice. The TCD50 increased with treatment time between 15 days and 10 weeks from 43 Gy to 102 Gy. The data can be well described by a single linear function. The dose recovered per day is 1.0 Gy. However, the data can also be adequately fitted by two components with an initial delay of about 30 days followed by a steep increase at a rate of 1.5 Gy per day. Assuming that the increase of TCD50 is solely caused by repopulation of clonogenic tumor cells, and that the cellular radiation sensitivity in vitro reflects the radiation sensitivity of FaDu cells in vivo, the doubling time of clonogenic tumor cells during treatment is estimated to be approximately 1.8 days for the one-component model and, after an initial delay, approximately 1.2 days for the two-component model. Both values are shorter than the doubling time of clonogenic cells in untreated FaDu tumors and similar to the potential doubling time determined by flow cytometry after BrdUrd labelling. It is concluded that the dose necessary to control FaDu squamous cell carcinoma increases considerably with increasing time of a fractionated radiation treatment. It appears most likely that this increase is caused by repopulation of clonogenic tumor cells; however, other mechanisms such as an increasing fraction of hypoxic tumor cells can not be ruled out at present.

Entities:  

Mesh:

Year:  1994        PMID: 7972907     DOI: 10.1016/0167-8140(94)90100-7

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  8 in total

1.  Potential clinical predictors of outcome after postoperative radiotherapy of non-small cell lung cancer.

Authors:  R Bütof; K Kirchner; S Appold; S Löck; A Rolle; G Höffken; M Krause; M Baumann
Journal:  Strahlenther Onkol       Date:  2014-01-12       Impact factor: 3.621

2.  Topotecan can compensate for protracted radiation treatment time effects in high grade glioma xenografts.

Authors:  Sophie Pinel; Pascal Chastagner; Jean-Louis Merlin; Christian Marchal; Alphonse Taghian; Muriel Barberi-Heyob
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

3.  Comparison of the response of human FaDu squamous cell carcinoma in nude mice after hypofractionated-accelerated regimens and "curative" fractionation schedules.

Authors:  S Appold; M Baumann; C Petersen; K Horn; F Eichhorn
Journal:  Strahlenther Onkol       Date:  1998-06       Impact factor: 3.621

4.  Quantitative Analysis of [18F]FMISO PET for Tumor Hypoxia: Correlation of Modeling Results with Immunohistochemistry.

Authors:  Kuangyu Shi; Christine Bayer; Sabrina T Astner; Florian C Gaertner; Peter Vaupel; Markus Schwaiger; Sung-Cheng Huang; Sibylle I Ziegler
Journal:  Mol Imaging Biol       Date:  2017-02       Impact factor: 3.488

5.  Mitomycin C in combination with radiotherapy as a potent inhibitor of tumour cell repopulation in a human squamous cell carcinoma.

Authors:  Wilfried Budach; F Paulsen; S Welz; J Classen; H Scheithauer; P Marini; C Belka; M Bamberg
Journal:  Br J Cancer       Date:  2002-02-01       Impact factor: 7.640

6.  Long-term outcomes of an esophagus-preserving chemoradiotherapy strategy for patients with endoscopically unresectable stage I thoracic esophageal squamous cell carcinoma.

Authors:  Tatsuya Suwa; Yuichi Ishida; Yoshiharu Negoro; Fusako Kusumi; Yoshio Kadokawa; Rihito Aizawa; Toshifumi Nakajima; Yoshiaki Okamoto; Yoshishige Okuno; Kazunari Yamada; Masakazu Ogura; Masao Murakami; Takashi Mizowaki
Journal:  Clin Transl Radiat Oncol       Date:  2021-08-11

7.  Hsp70--a biomarker for tumor detection and monitoring of outcome of radiation therapy in patients with squamous cell carcinoma of the head and neck.

Authors:  Mathias Gehrmann; Hanno M Specht; Christine Bayer; Markus Brandstetter; Barbara Chizzali; Marciana Duma; Stephanie Breuninger; Kathrin Hube; Sophie Lehnerer; Valerie van Phi; Eva Sage; Thomas E Schmid; Michael Sedelmayr; Daniela Schilling; Wolfgang Sievert; Stefan Stangl; Gabriele Multhoff
Journal:  Radiat Oncol       Date:  2014-06-09       Impact factor: 3.481

8.  The use of matrigel has no influence on tumor development or PET imaging in FaDu human head and neck cancer xenografts.

Authors:  Frederikke P Fliedner; Anders E Hansen; Jesper T Jørgensen; Andreas Kjær
Journal:  BMC Med Imaging       Date:  2016-01-14       Impact factor: 1.930

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.